With our unique low-cost allogeneic (CRX200, IND ready) and autologous (CRX100, Phase 1b) therapies, we have demonstrated the power of an engineered immune attack against the tumor microenvironment of intractable solid cancers, using living cells programmed to assemble and instruct the diverse molecules and complex immune pathways.

Apr 28, 2020 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100...

Dec 21, 2020 · Developed with technology exclusively licensed from Stanford University, CRX100 combines activated immune cells, known as cytokine-induced killer (CIK) cells, with a tumor-killing virus. As stand-alone therapies, these two agents have …

The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune response that may prevent relapse. It targets epithelial ovarian cancer, melanoma, non-small cell lung cancer, triple negative breast, gastric cancer, hepatocellular carcinoma ...

CRX-100 is being developed by BioEclipse Therapeutis for the treatment of patients with advanced solid tumors. (Sourced from: …

BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers.

The virus is designed to specifically attack and kill tumors and stimulate the patient’s immune system to attack the tumor cells. The goal is to eradicate the primary tumor and prevent relapse and recurrence.

Apr 28, 2020 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers.

Mar 5, 2021 · Investigators anticipate the CIK cells will protect the oncolytic virus and deliver it to the cancer cells in the body to attack primary tumors and metastatic disease. Preclinical studies have found that the combination may trigger a long-lasting immune response and protect against disease recurrence. 1.

The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune response that may prevent relapse. It targets epithelial ovarian cancer, melanoma, non-small cell lung cancer, triple negative breast, gastric cancer, hepatocellular carcinoma ...